Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Transcriptomic differences in MSA clinical variants

  • Pérez-Soriano, Alexandra
  • Arnal, Magdalena
  • Botta Orfila, Teresa
  • Giraldo, Darly
  • Fernández, Manel
  • Compta, Yaroslau
  • Fernández-Santiago, Ruben
  • Ezquerra, Mario
  • Tartaglia, Gian Gaetano
  • Martí, M. Josep
  • Catalan multiple system atrophy-registry (CMSAR)
Background: Multiple system atrophy (MSA) is a rare oligodendroglial synucleinopathy of unknown etiopathogenesis including two major clinical variants with predominant parkinsonism (MSA-P) or cerebellar dysfunction (MSA-C). Objective: To identify novel disease mechanisms we performed a blood transcriptomic study investigating differential gene expression changes and biological process alterations in MSA and its clinical subtypes. Methods: We compared the transcriptome from rigorously gender and age-balanced groups of 10 probable MSA-P, 10 probable MSA-C cases, 10 controls from the Catalan MSA Registry (CMSAR), and 10 Parkinson Disease (PD) patients. Results: Gene set enrichment analyses showed prominent positive enrichment in processes related to immunity and inflammation in all groups, and a negative enrichment in cell differentiation and development of the nervous system in both MSA-P and PD, in contrast to protein translation and processing in MSA-C. Gene set enrichment analysis using expression patterns in different brain regions as a reference also showed distinct results between the different synucleinopathies. Conclusions: In line with the two major phenotypes described in the clinic, our data suggest that gene expression and biological processes might be differentially affected in MSA-P and MSA-C. Future studies using larger sample sizes are warranted to confirm these results., We would like to thank all the patients for their always willing and generous collaboration. This project has been possible thanks to the funding from the Fundació Marató TV3 and CERCA Programme from Generalitat de Catalunya. We also thank the European Research Council RIBOMYLOME_309545 and Spanish Ministry of Economy and Competitiveness (BFU2017-86970-P). A.P.-S. was funded by a PHD4MD grant, which is a collaborative research training program for medical doctors. R.F.-S. was supported by a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (grant # SAF2015-73508-JIN), and a Miguel Servet grant from the Instituto de Salud Carlos III (grant # CP19/00048). M.F. was funded by María de Maeztu programme (grant # MDM-2017-0729). Thanks to Lara Nonell, head of the Human Computational Biology group in IMIM, for offering the computational resources in the institution and the help with data management.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels

  • Fernández-Santiago, Ruben
  • Esteve-Codina, Anna
  • Fernández, Manel
  • Valldeoriola, Francesc
  • Sanchez-Gómez, Almudena
  • Muñoz, Esteban
  • Compta, Yaroslau
  • Tolosa, Eduard
  • Ezquerra, Mario
  • Martí, Maria José
Type-2 diabetes (T2D) and glucose metabolic imbalances have been linked to neurodegenerative diseases, including Parkinson's disease (PD). To detect potential effects of different glucose levels on gene expression, by RNA-seq we analyzed the transcriptome of dermal fibroblasts from idiopathic PD (iPD) patients, LRRK2-associated PD (L2PD) patients, and healthy controls (total n = 21 cell lines), which were cultured at two different glucose concentrations (25 and 5 mM glucose). In PD patients we identified differentially expressed genes (DEGs) that were related to biological processes mainly involving the plasmatic cell membrane, the extracellular matrix, and also neuronal functions. Such pathway deregulation was largely similar in iPD or L2PD fibroblasts. Overall, the gene expression changes detected in this study were associated with PD independently of glucose concentration., This work was supported by CIBERNED / Instituto de Salud Carlos III (ISCIII) (grant PIE14/00061) (to M.-J.M.), and the Fondo de Investigaciones Sanitarias from ISCIII (grant PIE20/00259) (to M.E.). R.F.-S. was supported by a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (grant #SAF2015-73508-JIN), and a Miguel Servet grant from the Instituto de Salud Carlos III (grant #CP19/00048). A.E-C. was funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER. M.F. was funded through a María de Maeztu grant (#MDM-2017-0729). IDIBAPS receives funding from the CERCA Program from the Generalitat de Catalunya and the FEDER Program from the European Union.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson’s disease patients

  • Rabaneda, Neus
  • Vidal-Taboada, Jose M.
  • Valente, Tony
  • Ezquerra, Mario
  • Fernández-Santiago, Rubén
  • Martí, María-José
  • Compta, Yaroslau
  • Saura, Josep
  • Solà, Carme
Neuroinflammation, in which activated microglia are involved, appears to contribute to the development of Parkinson’s disease (PD). However, the role of microglial activation and the mechanisms governing this process remain uncertain. We focused on one inhibitory mechanism involved in the control of microglial activation, the microglia inhibitory receptor CD200R1, and its ligand CD200, mainly expressed by neurons. The human CD200R1 gene encodes two membrane-associated and two soluble protein isoforms and the human CD200 gene encodes full-length proteins (CD200full) but also truncated (CD200tr) proteins which act as CD200R1 antagonists. Little is known about their expression in the human brain under pathological conditions. We used human peripheral blood monocytes and monocyte-derived microglia-like cells from control subjects to characterize the expression of the CD200R1 mRNA variants, which showed stimulus-specific responses. We provide evidence of increased CD200R1 (mRNA variants and protein isoforms) and CD200 expression (CD200tr mRNA) in brain tissue of PD patients, mainly in the hippocampus, as well as increased CD200 expression (CD200full and CD200tr mRNAs) in iPSCs-derived dopaminergic neurons generated from skin fibroblasts of PD patients. Our results suggest that CD200-CD200R1 signalling is altered in PD, which may affect the microglial function and constitute a potential target in therapeutic strategies for PD., This study was supported by grants PI15/00033 and PI14/302 from the Instituto de Salud Carlos III (Spain) with joint financing by FEDER funds from the European Union. NRL was recipient of a FPU predoctoral contract from the Spanish Ministerio de Educación, Cultura y Deporte (FPU13/05491). TV received a JAE-Doc contract from CSIC, with joint financing by European Social Fund. RFS was supported by a Jóvenes Investigadores (JIN) grant from the Spanish Ministerio de Economía y Competitividad and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (SAF2015–73508-JIN), and a Miguel Servet grant from the Instituto de Salud Carlos III (CP19/00048).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transcriptomic differences in MSA clinical variants

  • Pérez-Soriano, Alexandra
  • Arnal, Magdalena
  • Botta Orfila, Teresa
  • Giraldo, Darly
  • Fernández, Manel
  • Compta, Yaroslau
  • Fernández-Santiago, Ruben
  • Ezquerra, Mario
  • Tartaglia, Gian Gaetano
  • Martí, M. Josep
  • Catalan multiple system atrophy-registry (CMSAR)
Background: Multiple system atrophy (MSA) is a rare oligodendroglial synucleinopathy of unknown etiopathogenesis including two major clinical variants with predominant parkinsonism (MSA-P) or cerebellar dysfunction (MSA-C). Objective: To identify novel disease mechanisms we performed a blood transcriptomic study investigating differential gene expression changes and biological process alterations in MSA and its clinical subtypes. Methods: We compared the transcriptome from rigorously gender and age-balanced groups of 10 probable MSA-P, 10 probable MSA-C cases, 10 controls from the Catalan MSA Registry (CMSAR), and 10 Parkinson Disease (PD) patients. Results: Gene set enrichment analyses showed prominent positive enrichment in processes related to immunity and inflammation in all groups, and a negative enrichment in cell differentiation and development of the nervous system in both MSA-P and PD, in contrast to protein translation and processing in MSA-C. Gene set enrichment analysis using expression patterns in different brain regions as a reference also showed distinct results between the different synucleinopathies. Conclusions: In line with the two major phenotypes described in the clinic, our data suggest that gene expression and biological processes might be differentially affected in MSA-P and MSA-C. Future studies using larger sample sizes are warranted to confirm these results., We would like to thank all the patients for their always willing and generous collaboration. This project has been possible thanks to the funding from the Fundació Marató TV3 and CERCA Programme from Generalitat de Catalunya. We also thank the European Research Council RIBOMYLOME_309545 and Spanish Ministry of Economy and Competitiveness (BFU2017-86970-P). A.P.-S. was funded by a PHD4MD grant, which is a collaborative research training program for medical doctors. R.F.-S. was supported by a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (grant # SAF2015-73508-JIN), and a Miguel Servet grant from the Instituto de Salud Carlos III (grant # CP19/00048). M.F. was funded by María de Maeztu programme (grant # MDM-2017-0729). Thanks to Lara Nonell, head of the Human Computational Biology group in IMIM, for offering the computational resources in the institution and the help with data management.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transcriptome analysis in LRRK2 and idiopathic Parkinson's disease at different glucose levels

  • Fernández-Santiago, Ruben
  • Esteve-Codina, Anna
  • Fernández, Manel
  • Valldeoriola, Francesc
  • Sanchez-Gómez, Almudena
  • Muñoz, Esteban
  • Compta, Yaroslau
  • Tolosa, Eduard
  • Ezquerra, Mario
  • Martí, Maria José
Type-2 diabetes (T2D) and glucose metabolic imbalances have been linked to neurodegenerative diseases, including Parkinson's disease (PD). To detect potential effects of different glucose levels on gene expression, by RNA-seq we analyzed the transcriptome of dermal fibroblasts from idiopathic PD (iPD) patients, LRRK2-associated PD (L2PD) patients, and healthy controls (total n = 21 cell lines), which were cultured at two different glucose concentrations (25 and 5 mM glucose). In PD patients we identified differentially expressed genes (DEGs) that were related to biological processes mainly involving the plasmatic cell membrane, the extracellular matrix, and also neuronal functions. Such pathway deregulation was largely similar in iPD or L2PD fibroblasts. Overall, the gene expression changes detected in this study were associated with PD independently of glucose concentration., This work was supported by CIBERNED / Instituto de Salud Carlos III (ISCIII) (grant PIE14/00061) (to M.-J.M.), and the Fondo de Investigaciones Sanitarias from ISCIII (grant PIE20/00259) (to M.E.). R.F.-S. was supported by a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI) (AEI/FEDER/UE) (grant #SAF2015-73508-JIN), and a Miguel Servet grant from the Instituto de Salud Carlos III (grant #CP19/00048). A.E-C. was funded by ISCIII /MINECO (PT17/0009/0019) and co-funded by FEDER. M.F. was funded through a María de Maeztu grant (#MDM-2017-0729). IDIBAPS receives funding from the CERCA Program from the Generalitat de Catalunya and the FEDER Program from the European Union.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Advances in Parkinson's Disease, 200 Years Later

  • Del Rey, Natalia López-González
  • Quiroga-Varela, Ana
  • Garbayo, Elisa
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Monje, Mariana H. G.
  • Trigo-Damas, Inés
  • Blanco-Prieto, María J.
  • Blesa, Javier|||0000-0002-4257-1325
When James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson's disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease

  • Gaig, Carles|||0000-0002-7113-8125
  • Ercilla, Guadalupe
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ezquerra, Mario|||0000-0003-3246-6641
  • Fernández-Santiago, Rubén|||0000-0002-4582-0702
  • Palou, Eduard|||0000-0003-1544-1485
  • Sabater, Lidia
  • Höftberger, Romana|||0000-0002-5769-1100
  • Heidbreder, Anna
  • Högl, Birgit
  • Iranzo, Alex|||0000-0002-5618-8271
  • Santamaria Cano, Joan|||0000-0003-0879-4135
  • Dalmau, Josep|||0000-0001-5856-2813
  • Graus Ribas, Francesc|||0000-0002-8924-8322
We investigated the associations with HLA and microtubule-associated protein tau (MAPT) H1 haplotype in anti-IgLON5 disease, a recently identified disorder characterized by gait instability, brainstem dysfunction, and a prominent sleep disorder in association with IgLON5 antibodies and pathologic findings of a novel neuronal-specific tauopathy. We compared the HLA alleles and MAPT H1/H1 genotype of 35 patients with anti-IgLON5 with healthy controls. The on-line server tool NetMHCIIpan 3.1 was used to predict the IgLON5 peptide binding to HLA Class II molecules. The HLA-DRB1*10:01-DQB1*05:01 haplotype was overrepresented in patients with anti-IgLON5 disease (OR = 54.5; 95% CI: 22.2-133.9, p < 0.0001). In addition, HLA-DQA was genotyped in 27 patients, and 25 (92.6%) of them had DQ molecules composed by DQA1*01 and DQB1*05 chains compared with 148/542 (27.3%) controls (OR = 43.9; 95% CI: 10.4-185.5, p < 0.0001). Patients DRB1*10:01 positive developed more frequently sleep or bulbar symptoms than those carrying other HLA alleles (70.0% vs 26.7%; p = 0.011). Prediction algorithms identified 2 IgLON5 peptides (1 located in the signal sequence) that showed strong binding to HLA-DRB1*10:01 and other HLA-DRB1, but not to HLA-DQA and HLA-DQB molecules. The MAPT H1/H1 homozygous genotype was present in 20/24 (83.3%) anti-IgLON5 Caucasian patients compared with 54/116 (46.5%) healthy controls (p = 0.0007). The robust association of anti-IgLON5 disease with distinct HLA Class II molecules supports a primary autoimmune origin. The significant association of MAPT H1 haplotype also suggests that an underlying neurodegenerative process could be involved in anti-IgLON5 disease.